Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Commentary

Commentary: COVID-19 and obesity pandemics converge into a syndemic requiring urgent and multidisciplinary action

Michael A. Hill a,⁎, James R. Sowers a, Christos S. Mantzoros b

a Dalton Cardiovascular Center, Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO, United States of America
b Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, The Section of Endocrinology, VA Boston Healthcare System and Harvard Medical School, Boston, MA, United States of America

ARTICLE INFO

While substantial evidence points towards obesity and associated cardiometabolic disorders being a major factor for poor outcomes in SARS-CoV2 infections (COVID-19), the complexity of the interplay between these two pandemics is becoming apparent. Indeed, as previously defined, this interaction between obesity and COVID-19 represents a ‘syndemic’ that requires both current and ongoing attention. At a mechanistic level the chronic inflammatory environment of obesity predisposes to life threatening events such as cytokine storm and enhanced coagulopathy. Obesity and its management are affected by diverse factors manifested at societal, educational, racial, and nutritional levels. A multidisciplinary approach is required to manage obese and type 2 diabetic patients, not only during the current COVID-19 crisis, but to decrease the growing burden of cardiometabolic disease and associated cardiovascular complications impeding future viral pandemics. Further, this syndemic has highlighted disparities in healthcare which need to be addressed to achieve equality in health outcomes in patients infected with COVID-19.

The current COVID-19 pandemic resulting from exposure to the RNA virus, SARS-CoV2, is a major cause of morbidity and mortality on a global scale. By the beginning of October 2020 there was more than 34,000,000 cases and over 1,000,000 deaths worldwide, with these numbers continuing to increase. Although initial emphasis was placed on its effects on the respiratory system it is now clear that COVID-19 is a systemic, multi-system disorder (Fig. 1). An apparent universal finding is that several chronic cardiometabolic disease states are associated with an increased predilection for adverse SARS-CoV2 infection outcomes. In particular, these conditions include diabetes, hypertension, cardiovascular disease (CVD) and chronic renal disease [1–9]. All of these chronic diseases are more common in males and in aging populations which are also populations with poorer outcomes in patients contracting SARS-CoV2 infection [10]. These observations suggest that there may be a common underlying denominator that predisposes to poorer outcomes in these populations. An integral underlying condition that links these disease states is obesity. To this point, increased adipose tissue mass, especially when deposited centrally, is a major risk factor for cardiometabolic abnormalities including insulin resistance, dyslipidemia, hypertension and systemic inflammation, which ultimately lead to diabetes, exacerbated hypertension, cardiovascular disease, NASH and chronic kidney disease [11–14].

Indeed, early reports from China and Italy indicated that obesity, even at relatively mild levels, predisposes to increased morbidity and mortality in patients with SARS-CoV2 infection [1,15], as was also reported in those with influenza A (H1N1) disease [16]. This relationship between obesity and poorer outcomes in COVID-19 infection has now been seen in a number of countries including the US, France, Spain and Mexico [15,17,18]. For example, increased risk for a poor Covid-19 outcome was seen at a BMI > 24.0 in a report from Shenzhen, China – a BMI that would be considered ‘normal’ in many societies, indicating that increasing risk starts with even high normal BMI and the risk increases progressively with increasing degrees of obesity. Subsequently, a number of early meta-analyses of studies from wide geographical regions have confirmed the impact of obesity on COVID-19 outcomes and have provided a more accurate effect estimate of the association. Further, the presence of obesity may shift the severity of COVID-19 infection and increased mortality to younger populations [19–21]. However, an important question is whether obesity is the root cause of the problem and/or whether its association with other cardiometabolic entities with the severity of COVID-19 infection and outcomes are independent.

A recent study reported in Metabolism [22] provided novel insights regarding the role of obesity and associated disorders in promoting poor outcomes in SARS-CoV2 infected patients. Obesity was identified as a critical underlying cause of poor outcome in a specific cohort of 200 infected Covid-19 patients in the Bronx borough in New York City. The
patient population in the Bronx cohort, unlike prior reported homogeneous COVID-19 populations, was largely of African American and Hispanic (approximately 85%) makeup. This ethnic breakdown is considerably different from an earlier study of a wider New York City area where these groups approximated some 50% of COVID-19 patients [23]. Importantly, the report from the Bronx included patients representing underserved and economically disadvantaged minorities; thus, revealing the outcomes of COVID-19 in this vulnerable population where there is a paucity of information. Another strength of this study was the use of multi-variable models to statistically dissect pathways of variables associated with the outcomes of interest and that severe obesity, assessed as a BMI of 35 kg/m² or greater, was treated as a dichotomous, as well as a continuous variable in this analysis. Thus, the authors were able to show that obesity is an independent predictor of poorer outcome with COVID-19 infections in this vulnerable population. This approach adjusted for associated diseases such as diabetes, age, hypertension and cardiovascular disease and thus excluded them as significant confounders in this association indicating that obesity is at the root cause of the problem.

Several recent papers in Metabolism (one a meta-analysis of 16 studies including nearly 110,000 infected patients [24]; a similar meta-analysis of 45,650 patients [25]; and the other a regional study) have now strengthened the observed relationship between obesity and adverse COVID-19 outcomes/severity. Further, these analyses suggest a relatively linear relationship between BMI and COVID-19 severity such that the patients classified as overweight also show an increased risk for a poor outcome or death. In the study of Du this relationship was again shown to be independent of a number of other comorbidities [24].

An additional consideration relates to the contribution of body composition and specific fat depots vs. overall obesity. In this regard, two recent brief retrospective studies [26,27] have reported that increased visceral fat, determined using CT scans, is predictive of the severity of COVID-19 infection as defined by the need for admission to intensive care units and mechanical ventilation. Further, increased visceral fat was more predictive of a severe outcome than was increased subcutaneous fat. Importantly, visceral fat accumulation is more closely associated to inflammatory disorders including the cardiometabolic syndrome and type 2 diabetes [28]. Both studies further provided evidence for the utility of CT scans routinely taken in the context of care to assess lung involvement also provide abdominal fat information in hospitalized COVID-19 patients were superior to BMI, particularly in aging populations where body composition changes markedly. Another study reported that the presence of fatty liver (metabolic associated fatty liver disease), another condition associated with excess body and visceral fat as determined by CT scans, was associated with a more severe clinical course for Covid-19 infection [29]. In this study obesity was defined as BMI >25 kg/m² perhaps indicating the importance of fat deposition in the liver as well as abdominal adiposity as opposed to BMI per se. Also, important to consider, body fat distribution for a given BMI is also impacted by other factors including sex and race. Relevant to this, using data from the UK Biobank, a population-based cohort study, Zhu et al. [30] examined the relationship between a calculated polygenic risk score for obesity and COVID-19 severity. A higher risk score for BMI was associated with COVID-19 outcome perhaps indicating a role for genetic predisposition for obesity and poor outcome [30]. While future research will be required to identify specific genetic mechanisms, this could conceivably lead to a more personalized medicine approach for prevention or treatment.

It has further been suggested that SARS-CoV2 infection may impact adipose tissue specifically associated with cardiovascular structures, specifically epicardial and perivascular fat [31–33]. Increased adipose tissue in theses organs has been associated with inflammation, immune cell activation and cardiovascular disorders. Specific involvement of these fat depots in the course of COVID-19 infection requires further study.

An important question regarding the mechanism(s) by which obesity predicts a poor outcome in heterogeneous COVID-19 populations including minority patients, as well as in more homogeneous populations from China, Italy and Spain. Suggested impacting factors have included an increased susceptibility to infection; mechanical factors impairing ventilation (obesity hypoventilation syndrome and obstructive sleep apnea), particularly when intubation is required [34,35]; obesity-related abnormalities in coagulation, fibrinolysis, inflammation, oxidative stress and disturbances in microcirculatory function [36–38]. In this regard, obesity represents a state of adipose tissue and systemic inflammation [39,40] (Fig. 1).

Metabolic changes in adipose tissue in the setting of obesity include expansion of inflammatory immune cell populations, increased secretion of inflammatory molecules and hormones including tumor necrosis factor alpha, interleukin 6, angiotensinogen, angiotensin II, aldosterone, leptin, resistin, and monocyte chemoattractant protein-1, and reduced

---

**Fig. 1.** Obesity is a contributor to poor outcomes in COVID-19. While obesity is a common factor in several comorbidities that have been implicated as risk factors for morbidity and mortality associated with COVID-19 infection, complex interactions exist not only at the cellular level but also the multi-factorial issues underlying fat distribution. This schematic has been drawn on ideas presented in recent publications [35,38,67]. GIT – gastrointestinal tract; NAFLD – non-alcoholic fatty liver disease.
secretion of the anti-inflammatory molecule adiponectin. This adipose tissue-induced inflammatory state is evidenced by increased levels of interleukin 6 and other inflammatory cytokines seen with coronavirus infections including SARS-CoV, MERS-CoV and SARS-CoV2 [41]. Elevated circulating levels of these inflammatory cytokines likely impairs vascular insulin metabolic signaling and associated nitric oxide mediated smooth muscle cell relaxation. There is increased recruitment and activation of pro-inflammatory immune cells into the vasculature, which then contribute to development of increased vascular permeability which enhances the ability of the virus to invade tissues such as the heart, vasculature, kidney and gut. Thus, the “inflammatory storm” seen with this disease may be coupled with an overactive immune system that exists in obesity.

Adipose tissue has also been suggested to act as reservoir for the SARS-CoV2 virus, contributing to viral shedding and associated amplification of cytokine production [35]. This, however, requires further investigation as visceral fat samples from a small number (n = 4) COVID-19 positive patients undergoing abdominal surgery were negative for viral RNA as detected by quantitative PCR [42]. Of additional importance to the relationship between obesity and COVID-19 infection is the involvement of the renin angiotensin II aldosterone system (RAAS). Obesity is associated with systemic and fat tissue RAAS activation with elevated aldosterone levels, which contribute to inflammation [43], while ACE2 has been identified as the receptor for cellular uptake of SARS-CoV2 [44] and is expressed in adipose tissue [35]. While a preliminary study has reported increased ACE2 mRNA expression in visceral compared to subcutaneous adipose tissue (Favre, under review) further studies are required to determine whether ACE2 protein is upregulated with visceral adiposity, particularly in the context of SARS-CoV-2 infection. Related to this, a further study has reported that following weight loss, mRNA expression for ACE2 in subcutaneous adipose tissue decreased in a cohort of non-COVID patients (n = 143; BMI > 27 kg/m2) [45]. Interestingly, subjects showing the greatest decrease in ACE2 mRNA showed a higher degree of skeletal muscle insulin resistance, suggesting a relationship between ACE2 and insulin sensitivity [45].

The relevance of these finding to SARS-CoV2 infection, however, requires further study. Regardless of the exact cellular mechanisms, obesity and the associated systemic inflammatory state may be a common denominator underlying the poorer outcomes in patients with underlying diabetes, hypertension and CVD, especially in minorities with a high prevalence of these disorders. To this point, COVID-19 has been described as a modern day example of Virchow’s Triad (damage to the vascular wall, stasis/impaired flow and hypercoagulation) exacerbated by obesity and associated metabolic abnormalities [38] (Fig. 1).

Suboptimal diet is a known cause of the cardiometabolic syndrome, diabetes and CVD with quality of diet being affected by race, ethnicity, and socioeconomic status [46]. Nutritional status further impacts immune function and levels of systemic inflammation [47]. As a result of such information, the issue of maintaining an appropriate nutritional diet during the COVID-19 pandemic has been raised and is of particular importance given the COVID-19 pandemic converges with the obesity pandemic to create a syndemic. In particular, the benefit of a Mediterranean Diet (MD) rich in fruits, vegetables, cereals, legumes, fish and monounsaturated/polyunsaturated fatty acids has been advocated. Importantly, consumption of a MD has been linked to having cardiovascualr and general health benefits including through decreasing levels of obesity and exerting favorable effects on components of the cardiometabolic syndrome. Mechanistically the benefits of a MD may result from lower energy density, higher fiber intake, reduced intake of saturated fats and improved antioxidant defense mechanisms. Even in areas where it may be expensive to buy fruits and vegetables or other more expensive components of the MD, consumption of less costly dried fruits such as raisins/ which have anti-oxidative and inflammatory activities [48], could potentially benefit or prevent severe infections [49,50]. Relevant to the outcome severity for COVID-19 infection such diets have been reported to decrease systemic inflammation and blood coagulation [51]. Further, a MD has been shown to exert beneficial effects in those with the cardiometabolic syndrome [52] and diabetes [53,54]. In order to assess the benefits of a MD in those with COVID-19 studies have been initiated during lockdown periods in both Spain (COVIDiet Study [55]) and Italy (EHLCCOVID19) [56]. Importantly, the Italian study also assesses lifestyle habits in terms of smoking, sleep quality, physical activity and shopping choices. While both studies indicate there is good short-term adherence to the MD they further seek to describe long term adherence and impact on chronic disease including susceptibility and outcomes to COVID-19. As inexpensive diets high in refined carbohydrates, especially those containing high amounts of fructose corn syrup, promote obesity and type 2 diabetes [57,58] consideration should also be given to restricting their intake or possibly following vegetarian/plant-based diets which have been shown to have beneficial effects on obesity and CV health [59].

The possible role of dietary supplements in COVID-19 prevention and treatment has been raised in both the popular press and medical literature [60] and considerable interest has been directed towards a possible association between low vitamin D levels and poorer outcomes of COVID-19 infection [61]. Interestingly, and relevant to the above discussion, a recent studied showed that adherence to a MD both decreased obesity and enhanced vitamin D levels [62]. As vitamin D deficiency has been suggested to be common, particularly in people of African American and Hispanic descent, it has been proposed that efforts should be made to correct low vitamin D levels in communities at risk for COVID-19 infection [63] until randomized clinical trials confirm its protective role or alternatively show that the observed associations might be due to uncontrolled confounding by obesity or other factors. Collectively, these observations also support the need to consider the role played by micronutrients in healthy diets in reducing inflammation and minimizing risk of infection.

Given the contribution of obesity and cardiometabolic comorbidities to poor outcomes following COVID-19 infection, pharmacological treatments should be prioritized towards body weight loss and decreasing CVD risk factors. Consistent with this approach glucose lowering agents, incretins and SGLT2 inhibitors represent potential therapeutic classes meeting this aim [64,65]. Adequate preventative management of glycemia and lipids, along with monitoring of blood pressure and physical activity in patients with diabetes during the COVID-19 pandemic has recently been highlighted [66].

Also, increasingly recognized is that the impact of obesity needs to be considered beyond mechanistic interactions at a cellular and organ level. Indeed, psychological and societal factors including ethnic differences, health and nutritional disparities [67–72] and weight stigma [73] should be taken into consideration The impact of obesity in specific ethnic/racial groups has been similarly observed in other Northern and Central American minority communities including Native Americans and people of Mexican/Hispanic descent. This represents a considerable health and resource concern to these communities as the prevalence of adult obesity in Mexico is approximately 40% in women and 27% in men. Similarly, the prevalence of obesity (BMI > 30 kg/m2) in Native Americans in the US is greater than 48% [https://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lnvid=40]. The widespread finding of an association between obesity, especially abdominal obesity, and COVID-19 severity strengthens the likelihood of a causative relationship for poor outcome in these minority populations and likely applies to other racial minorities showing poorer COVID-19 outcomes [72] [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/coronavirusrelateddeathsbyethnicgroup englandandwales/2/march2020to10april2020#ethnic-breakdown-of-deaths-by-age-and-sex].

Recently, in the context of COVID-19 outcomes, the complex relationships between health disparities and obesity have been raised [67,69,70]. Access to healthy foods, medical services, public health initiatives and nutritional education contribute to poor nutrition and
obesity, particularly in disadvantaged communities. Such factors are considered to favor the excess consumption of nutrient dense foods, high in refined carbohydrates, that lead to obesity [74]. This situation appears to be further complicated by socioeconomic factors, leading to denser living and work environments that does not favor social distancing or the ability to 'work from home'. Related to this, Townsend et al. have provided a very interesting and important perspective on the relationship between obesity and the course of COVID-19 infection, emphasizing the impact of an obesity stigma in leading to health disparities [73]. Accordingly, this stigma may be reflected in both a patient’s reluctance to seek healthcare, and poorer care as a result of a negative stereotype that healthcare providers may unwittingly apply to this population. Both of these situations add to the mechanistic and social interactions that occur between the obese state and poor COVID-19 infection outcomes (Fig. 1).

In 2017 The Lancet expanded on the term Syndemics (as introduced by Singer [75]), as “a conceptual framework for understanding diseases or health conditions that arise in populations and that are exacerbated by the social, economic, environmental, and political milieu in which a population is immersed” [76]. It has become clear that the coexisting COVID-19 pandemic and the growing obesity epidemic combine to fit the definition of a syndemic and represent a global challenge requiring research, public health, nutrition and educational approaches. This dire situation is clearly exacerbated by reduced availability of affordable, high quality nutrition [77].

In summary, recently published studies indicate that obesity and the associated inflammatory state represent an independent risk factor for a more severe clinical course during SARS-CoV-2 infection. As recently highlighted [78] by Singer, the assessment of COVID-19 patients in terms of anthropometric and metabolic data should be considered an important component of assessing patient risk for possible poor outcomes. Further, the increasing prevalence of obesity and related cardiometabolic disorders [79] will likely represent challenges to clinical management during the ongoing COVID-19 pandemic and future pandemic viral exposures. Preemptive approaches, at multiple levels, will be required to address the complex problem of obesity including maintenance of healthy weight, provision of access to affordable and nutritious foods, and attention to psychosocial issues in these patients (Fig. 1). Finally, vigilance will need to paid to possible long-term medical consequences of SARS-CoV-2 infection in surviving obese patients.

Declaration of competing interest

No conflicts of interest.

References

[1] Cai Q, Chen F, Wang T, Liu X, Wu Q, He Q, et al. Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1352–8.
[2] Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55(5).
[3] Falagas ME, Kompoti M. Obesity and in-hospital mortality. Lancet Infect Dis. 2006;6(7):438–46.
[4] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 infected patients with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574–81. https://doi.org/10.1001/jama.2020.5394.
[5] Hill MA, Mantzoros C, Sowers JR. Commentary: COVID-19 in patients with diabetes. Metabolism. 2020;107:154217.
[6] Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–6. https://doi.org/10.1001/jama.2020.4683.
[7] Rebolles E, Moriconi D, Verdi A, Taddess S, Foschi D, Nannipieri M. Letter to the editor: importance of metabolic health in the era of COVID-19. Metabolism. 2020;108:154247.
[8] Zhou F, Yu T, Hu T, Fan G, Li Y, Zhu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
[9] Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2(7):572–85.
[40] Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne). 2012;3:181.

[41] Moore JR, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368(6490):473–4.

[42] Safari S, Keyhani H, Alamdari NM, Dehghanian A, Hashemi MR, Honar BN, et al. Abdominal surgery in patients with COVID-19: detection of SARS-CoV-2 in abdominal and adnexal tissues. Ann Surg. 2020;272(3):e253–6. https://doi.org/10.1097/SLA. 0000000000004165 Online ahead of print.

[43] Lstraf G, Sowers JR. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the renin-angiotensin-aldosterone system. Horm Mol Biol Invest. 2013;15(2):49–57.

[44] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Metabolic impact of weight loss induced reduction of adipose ACE-2 potential implication in COVID-19 infections? Metabolism. 2020;113:154401. https://doi.org/10.1016/j.metabol.2020.154401 Online ahead of print.

[45] Kris-Etherton PM, Petersen KS, Velarde G, Barnard ND, Miller M, Ros E, et al. Barriers, opportunities, and challenges in addressing disparities in diet-related cardiovascular disease in the United States. J Am Heart Assoc. 2020;9(7):e014433.

[46] Silvero R, Goncalves DC, Andrade MF, Seelaender M. Coronavirus disease 2019 (COVID-19) and nutritional status: the missing link? Adv Nutr. 2020;11(2). https://doi.org/10.1093/advances/nmaa125 Online ahead of print.

[47] Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. Ethnic disparities in hospitalization for COVID-19 in Europe: a review of current and emerging treatments. Diabetes Ther. 2020;11(6):1199–216.

[48] Ghosh-Swably OR, Goodman SG, Leiter LA, Cheng A, Connolly KA, Fitchett D, et al. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomized cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8(5):418–35.

[49] Bornstein SR, Rubino F, Khunti K, Stringer D, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–59.

[50] Adams KK, Baker WL, Sobieraj DM. Myth busters: dietary supplements and COVID-19. Ann Pharmacother. 2020;54(8):820–6.

[51] D’Avolio A, Avatareano V, Manca A, Cusato J, De Nicolao A, Lucchini R, et al. 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients. 2020;12(5).

[52] Barre A, Muscogna G, Saudisso D, Pugliese G, de Alteris C, Colao A, et al. Influence of the Mediterranean diet on 25-hydroxyvitamin D levels in adults. Nutrients. 2020;12(2).

[53] Manson JE, Barrus SK. Commentary. Eliminating vitamin D deficiency during the COVID-19 pandemic: a call to action. Metabolism. 2020;112:154322. https://doi.org/10.1016/j.metabol.2020.154322 Online ahead of print.

[54] Williams DM, Nawaz A, Evans M. Drug therapy in obesity: a review of current and emerging treatments. Diabetes Ther. 2020;11(6):1199–216.

[55] Adams KK, Baker WL, Sobieraj DM. Myth busters: dietary supplements and COVID-19. Ann Pharmacother. 2020;54(8):820–6.

[56] Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-socio-cultural context. Med Anthropol Q. 2003;17(4):423–40.

[57] Hall KD, McClinton A. The COVID-19 pandemic: a call to action to identify and address racial and ethnic disparities. J RacialEthn Health Disparities. 2020;7(3):319–22.

[58] Vepa A, Bae JP, Ahmed F, Pareek M, Khunti K. COVID-19 and ethnicity: a novel pathophysiological role for inflammation. Diabetes Metab Syndr. 2020;14(5):1043–51.

[59] Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divali P, et al. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. EClinicalMedicine. 2020;23:100404.

[60] Townsend MJ, Kyle TK, Stanford FC. Commentary: COVID-19 and obesity: exploring biologic vulnerabilities, structural disparities, and weight stigma. Metabolism. 2020;154316.

[61] Hall KD, Ayuketah A, Byrchatya R, Cai H, Cassimatis T, Chen KY, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30(1):67–77.e3.

[62] Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-socio-cultural context. Med Anthropol Q. 2003;17(4):423–40.

[63] Thakur N, Lovinsky-Desir S, Bime C, Wisnivesky JP, Celedon JC, Health, Equality Diversity Committee of the American Thoracic Society. The structural and social determinants of the racial/ethnic disparities in the US COVID-19 pandemic: what’s our role? Am J Resp Crit Care Med. 2020;202(7):943–9. https://doi.org/10.1164/ rccm.202005-1523PP.

[64] Laurencin CT, McClinton A. The COVID-19 pandemic: a call to action to identify and address racial and ethnic disparities. J Racial Ethn Health Disparities. 2020;7(3):319–22.

[65] Vega A, Bae JP, Ahmed F, Pareek M, Khunti K. COVID-19 and ethnicity: a novel pathophysiological role for inflammation. Diabetes Metab Syndr. 2020;14(5):1043–51.

[66] Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divali P, et al. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. EClinicalMedicine. 2020;23:100404.

[67] Townsend MJ, Kyle TK, Stanford FC. Commentary: COVID-19 and obesity: exploring biologic vulnerabilities, structural disparities, and weight stigma. Metabolism. 2020;154316.

[68] Hall KD, Ayuketah A, Byrchatya R, Cai H, Cassimatis T, Chen KY, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. Cell Metab. 2019;30(1):67–77.e3.

[69] Singer M, Clair S. Syndemics and public health: reconceptualizing disease in bio-socio-cultural context. Med Anthropol Q. 2003;17(4):423–40.